Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology, University Medical Centre Goettingen, Georg August University, Goettingen, Germany; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, School of Medicine Munich, Munich, Germany; Sonderforschungsbereich/Collaborative Research Centre 1321 Modeling and Targeting Pancreatic Cancer, Munich, Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK) Munich Site, Munich, Germany; and Department of Gastroenterology, Endocrinology, Infectiology and Metabolism, Philipps University Marburg, Marburg, Germany.
Physiol Rev. 2020 Oct 1;100(4):1707-1751. doi: 10.1152/physrev.00042.2019. Epub 2020 Apr 16.
Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment (TME) that dynamically evolves during tumor progression. The TME consists of different non-neoplastic cells such as cancer-associated fibroblasts, immune cells, endothelial cells, and neurons. Furthermore, abundant extracellular matrix components such as collagen and hyaluronic acid as well as matricellular proteins create a highly dynamic and hypovascular TME with multiple biochemical and physical interactions among the various cellular and acellular components that promote tumor progression and therapeutic resistance. In recent years, intensive research efforts have resulted in a significantly improved understanding of the biology and pathophysiology of the TME in PDAC, and novel stroma-targeted approaches are emerging that may help to improve the devastating prognosis of PDAC patients. However, none of anti-stromal therapies has been approved in patients so far, and there is still a large discrepancy between multiple successful preclinical results and subsequent failure in clinical trials. Furthermore, recent findings suggest that parts of the TME may also possess tumor-restraining properties rendering tailored therapies even more challenging.
胰腺导管腺癌 (PDAC) 属于人类最致命的实体肿瘤之一。PDAC 的一个组织学显著特征是明显的肿瘤微环境 (TME),它在肿瘤进展过程中动态演变。TME 由不同的非肿瘤细胞组成,如癌相关成纤维细胞、免疫细胞、内皮细胞和神经元。此外,丰富的细胞外基质成分(如胶原和透明质酸)以及基质细胞蛋白形成了一个高度动态和低血管的 TME,其中各种细胞和无细胞成分之间存在多种生化和物理相互作用,促进肿瘤进展和治疗耐药性。近年来,大量的研究工作极大地提高了人们对 PDAC 中 TME 的生物学和病理生理学的认识,新兴的基质靶向方法可能有助于改善 PDAC 患者的灾难性预后。然而,迄今为止,还没有一种抗基质疗法被批准用于患者,而且在多个成功的临床前结果和随后的临床试验失败之间仍然存在很大的差距。此外,最近的研究结果表明,TME 的某些部分也可能具有抑制肿瘤的特性,这使得量身定制的治疗更加具有挑战性。